# Final independent code review

A read-only reviewer inspected the current diff against 548b537b92ead41093910cc54ef804be219c29b4: the source adapter and schemas, source-scoped import and hash idempotency, additive migration/preflight, search/detail/UI, automated tests and evidence documentation.

No critical or important findings were reported. The reviewer did not execute tests or access any database or device; execution evidence was obtained separately by the primary agent.

The original minor report-path issue was corrected: the CLI reserves a writable, new destination with fs.open(wx) before its first import transaction. A real isolated-database test verified EEXIST with an unchanged persisted batch count; a subsequent new-destination run skipped all 1,000 records.

Failure-report writing is best effort: a disk failure may leave an incomplete/unparseable local report. Persisted transactional batch/version audits remain authoritative for recovery; no automatic rollback, overwrite or deletion is attempted after an I/O error. This limitation does not affect the successful import evidence.

Release boundaries remain explicit: unreviewed historical metadata in an opt-in local test preview, no phone database migration, no public release, no current regulatory/pricing/clinical claims, no pharmacy or marketplace writes.
The final visual review added the existing source package ID to historical search cards, because distinct packages can share a brand name. The reviewer inspected the additive SELECT/UI/test change and reported no findings. The primary agent rebuilt and reran acceptance afterward; see final execution artifacts.
